ArticleScience advances2024
Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
- Review
- CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer.Cancer & metabolism · 2026Article
- Integrative Mendelian Randomization and Multiomics Analysis Identifies CAF-Derived Complement Factor B as a Prognostic Biomarker and Therapeutic Vulnerability in Breast Cancer.Human mutation · 2026Article
- Immunotherapy for small cell lung cancer: current challenges and prospects.Experimental hematology & oncology · 2025Review
- Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT-00420) Alone or With Chemotherapy Inhibit the Growth of SCLC.Cancer science · 2025Article
- PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells.Cell death & disease · 2024Article
- Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung Cancer.Molecular cancer research : MCR · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Chiho KimDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0001-6846-5515
Xu-Dong WangDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-8265-1485
Zhengshuai LiuDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0009-0003-2544-947X
Jianwei HaoDepartment of Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.ORCID 0009-0005-5038-5783
Shuai WangDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-5432-4970
Peng LiDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-7751-1146
Zhenzhen ZiDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-3573-5838
Qing DingDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Seoyeon JangDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-8483-7275
Jiwoong KimQuantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-0220-9329
Yikai LuoDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7589-7981
Kenneth E HuffmanHamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, Departments of Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Shreoshi Pal ChoudhuriHamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, Departments of Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Sofia Del RioDepartment of Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.ORCID 0009-0000-0043-9417
Ling CaiQuantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Han LiangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-7633-286X
Benjamin J DrapkinHamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, Departments of Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-4824-7243
John D MinnaHamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, Departments of Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-7776-0767
Yonghao YuDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0001-8414-4666
The University of Texas Southwestern Medical Center · USColumbia University · USThe University of Texas MD Anderson Cancer Center · US
Funding
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4MUT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MCoordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9MDeveloping ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancerU01CA213338 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MINNA, JOHN D. · 2017 to 2021
$3.0MPosttranslational Regulation of Cell Growth and Stress ResponsesR35GM134883 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI YU, YONGHAO · 2020 to 2024
$2.7MA Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular CondensationR01NS122533 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI Yonghao Yu · 2022 to 2026
$2.0MDissecting and overcoming cross-resistance to DNA damaging agents in SCLCK08CA237832 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI DRAPKIN, BENJAMIN J · 2020 to 2024
$1.2MSite-Specific Antibody for Protein Poly-ADP-RibosylationR21CA261018 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI YU, YONGHAO · 2021 to 2021
$421kNCI NIH HHS K08 CA237832NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA070907NCI NIH HHS R21 CA261018NCI NIH HHS U01 CA213338NCI NIH HHS U24 CA213274NIGMS NIH HHS R35 GM134883NINDS NIH HHS R01 NS122533
Abstract
Although
Indexed as
Lung NeoplasmsSmall Cell Lung CarcinomaBRCA1 ProteinBRCA2 ProteinCell Line, TumorHumansOncogene ProteinsPoly(ADP-ribose) Polymerase InhibitorsProteomicsTumor Suppressor ProteinsUbiquitin-Protein LigasesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanHUWE1 protein, humanOncogene ProteinsPoly(ADP-ribose) Polymerase InhibitorsTumor Suppressor ProteinsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.